Reboxetine
| Evidence Level: L2 | Predicted Indications: 10 |
Table of Contents
Using the report structure to synthesize this multi-candidate evidence pack. Note: predicted_indications[0] (benign paroxysmal torticollis of infancy) is a pure TxGNN topology artifact with zero supporting evidence — I’m leading with the best-evidenced candidate (dysthymic disorder, L2) instead, and flagging the mechanistically implausible top-ranked hits separately, since presenting rank-1 as the headline would be misleading.
Reboxetine: From Major Depressive Disorder to Dysthymic Disorder
One-Sentence Summary
Reboxetine is a selective norepinephrine reuptake inhibitor (NRI) originally developed and approved (e.g., UK, 1997) for major depressive disorder, with off-label use in panic disorder. Among 10 TxGNN-predicted indications, Dysthymic Disorder has the strongest supporting evidence — 9 publications including placebo-controlled RCT meta-analyses — while the model’s single highest-scoring prediction (benign paroxysmal torticollis of infancy) has no clinical trials, no literature, and no plausible mechanism, and should be disregarded.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Major depressive disorder (per DrugBank pharmacology clinical_use: also used for panic disorder, ADHD; not formally in taiwan_regulatory) |
| Predicted New Indication | Dysthymic Disorder |
| TxGNN Prediction Score | 99.87% |
| Evidence Level | L2 |
| India Market Status | Not marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
All Predicted Indications at a Glance
| Rank | Disease | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|---|
| 1 | Benign paroxysmal torticollis of infancy | 99.92% | L5 | Hold – no mechanistic link |
| 2 | Agoraphobia | 99.91% | L3 | Research Question |
| 3 | Dysthymic disorder | 99.87% | L2 | Research Question |
| 4 | Ohdo syndrome and variants | 99.76% | L5 | Hold – no mechanistic link |
| 5 | Melancholia | 99.74% | L2 | Research Question (efficacy controversial) |
| 6 | Neurotic depression | 99.74% | L2 | Research Question (overlaps with #5) |
| 7 | Blepharophimosis–intellectual disability syndrome, Ohdo type | 99.70% | L5 | Hold – no mechanistic link |
| 8 | Neurotic disorder | 99.66% | L5 | Hold – no evidence |
| 9 | Keppen-Lubinsky syndrome | 99.54% | L5 | Hold – no mechanistic link |
| 10 | Ligneous conjunctivitis | 99.40% | L5 | Hold – no mechanistic link |
Five of the ten predictions (ranks 1, 4, 7, 9, 10) are rare genetic syndromes with no plausible pharmacological connection to a norepinephrine reuptake inhibitor — these are graph-topology artifacts of the TxGNN model and are not clinically actionable.
Why is This Prediction Reasonable?
Reboxetine is a highly selective norepinephrine transporter (NET/SLC6A2) inhibitor with low affinity for serotonin or dopamine transporters and negligible affinity for other CNS receptors (confirmed via DrugBank pharmacology data: target NET, human SLC6A2, CAS 71620-89-8). It was the first selective NRI brought to market, approved in the UK in 1997 as Edronax® for acute and maintenance treatment of major depressive illness.
Dysthymic disorder (persistent depressive disorder) sits on the same depressive spectrum as major depressive disorder and shares the underlying monoamine-deficiency pathophysiology that reboxetine’s original indication targets. This is not merely theoretical: reboxetine’s original clinical development program directly included dysthymic patients — the pivotal review by Burrows et al. (1998, PMID 9818623) explicitly evaluated reboxetine across “major depressive disorders and dysthymia” using pooled data from 8 placebo/active-controlled and 4 open-label trials (n=690).
The five rare-syndrome predictions (torticollis, Ohdo syndrome, Keppen-Lubinsky syndrome, blepharophimosis–ID syndrome, ligneous conjunctivitis) have no shared pathway with NET inhibition — these are genetic/structural conditions (e.g., KAT6A/KAT6B, KCNJ6, plasminogen deficiency) and the high TxGNN scores reflect graph embedding proximity, not biology.
Clinical Trial Evidence
Currently no related clinical trials registered for Dysthymic Disorder specifically (or for any of the 10 predicted indications — the evidence pack contains no clinicaltrials.gov or ICTRP entries across all candidates).
Literature Evidence
(Dysthymic Disorder — highest evidence-level candidate)
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 21527126 | 2011 | Meta-analysis (placebo-controlled RCTs) | J Clin Psychiatry | Antidepressants show significant efficacy vs. placebo in dysthymic disorder, comparable response pattern to MDD |
| 10628889 | 1999 | Double-blind RCT (vs. imipramine) | J Affect Disord | Reboxetine vs. imipramine in elderly depressive patients; comparable efficacy with better tolerability profile |
| 9818623 | 1998 | RCT review (8 controlled + 4 open trials, n=690) | J Clin Psychiatry | Reboxetine effective and well-tolerated for major depressive disorder and dysthymia, short- and long-term |
| 10984724 | 2000 | Open-label long-term study | Int J Geriatr Psychiatry | Reboxetine maintenance therapy in 160 elderly patients with MDD or dysthymia; effective and well-tolerated |
| 10616869 | 1999 | Pilot study | J Geriatr Psychiatry Neurol | Reboxetine titrated to 8mg/day in elderly depressed/dysthymic patients; tolerability assessed |
| 15183602 | 2004 | Open-label adjunct study | J Affect Disord | Reboxetine as add-on therapy for partial/non-responders to prior antidepressants |
| 15358987 | 2004 | Physiological/sleep study | J Psychopharmacol | Reboxetine’s effect on sleep architecture and nocturnal cardiac autonomic activity in 12 dysthymic patients |
| 10839469 | 2000 | Pharmacokinetic study | Int J Clin Pharmacol Ther | PK characterization of reboxetine in elderly depressive patients |
| 21057421 | 2010 | Mechanistic/lab study | Psychiatria Danubina | NK cell cytotoxicity differences between major depression and dysthymia |
Note on secondary candidates (Melancholia / Neurotic Depression, L2): these share largely overlapping literature with dysthymia but efficacy is more contested — the 2018 Cipriani et al. network meta-analysis (PMID 29477251, Lancet) ranked reboxetine among the less-favorable antidepressants for efficacy, and a dedicated systematic review (Eyding et al. 2010, BMJ, PMID 20940209) raised significant publication-bias concerns specific to reboxetine’s depression trial data. Treat these two as the same underlying question as dysthymia rather than independent new indications.
India Market Information
Reboxetine currently has no registered products (market_status: Not marketed, total_licenses: 0). No authorization records are available for review.
Safety Considerations
Please refer to the package insert for safety information.
(No usable warnings, contraindications, or drug-drug interaction data are currently available. The single safety.ddi entry describes reboxetine’s own pharmacological target — NET/SLC6A2 — rather than an interacting drug, and is not a genuine interaction record.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- A Blocking data gap (DG001: missing India/local label warnings and contraindications) prevents any S1 safety assessment, regardless of indication.
- Reboxetine has zero market presence locally (0 registrations), adding regulatory/access barriers.
- Even the best-evidenced candidate (dysthymic disorder, L2) rests on trials designed for the original MDD indication rather than dysthymia-specific confirmatory studies, and closely related candidates (melancholia, neurotic depression) carry documented efficacy/publication-bias controversy.
- 5 of 10 TxGNN predictions are mechanistically implausible rare-disease matches and should not be pursued.
To proceed, the following is needed:
- Resolve DG001: obtain official product label (warnings, contraindications) from the relevant regulatory source before any S1 safety evaluation.
- Resolve DG002: confirm detailed MOA documentation beyond DDI-derived pharmacology data.
- If pursuing dysthymic disorder specifically, commission or identify a dysthymia-specific RCT rather than relying on pooled MDD/dysthymia trial data.
- Reassess reboxetine’s controversial efficacy profile (publication bias, Cipriani ranking) before allocating further resources to the depression-spectrum candidates.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.